Circio to Present Financing Update and New circVec Gene Therapy Data in February Webcast

Targovax ASA ( (GB:0RIS) ) has provided an update.

Circio Holding ASA will host a live webcast on 26 February 2026 to provide investors and stakeholders with a corporate update and new scientific data. Management will outline the company’s progress in advancing its circVec circular RNA expression platform, which has shown markedly longer RNA half-life and higher protein expression than conventional mRNA-based systems in preclinical studies.

During the event, CEO Erik Digman Wiklund will review Circio’s recently completed and described as highly successful financing transactions and present the business outlook for 2026. CTO Thomas Birkballe Hansen will detail new in vivo results, including strong performance of circVec in additional gene therapy areas and further validation of earlier findings, underscoring Circio’s ambition to position circVec as a potential new standard in gene expression technology.

More about Targovax ASA

Circio Holding ASA is a biotechnology company specializing in circular RNA expression technology for gene and cell therapies. Through its proprietary circVec platform, developed by wholly owned subsidiary Circio AB in Stockholm, the company aims to deliver next-generation RNA, DNA and viral therapeutics with significantly improved RNA stability and protein expression for applications in genetic medicine, cell therapy and chronic diseases.

Average Trading Volume: 3,921,135

Current Market Cap: NOK248.6M

Find detailed analytics on 0RIS stock on TipRanks’ Stock Analysis page.